Sanofi SA

SAN: XPAR (FRA)
View Stock Summary
Morningstar Rating for StocksFair ValueEconomic MoatCapital Allocation
$jTLOCK|p>xFLOCK|!C!NvJp

Led by Dupixent, Solid Immunology Position Helps Support Steady Long-Term Growth for Sanofi

Business Strategy and Outlook

Sanofi's wide lineup of branded drugs and vaccines and robust pipeline create strong cash flows and a wide economic moat. Growth of existing products and new product launches should help offset upcoming patent losses.

Sponsor Center